Newer Antiseizure Medications: 3 Critical Clinical Insights
An evidence synthesis comparing efficacy parity, tolerability differences, and pregnancy safety data across second- and third-generation agents and older anticonvulsants.
One-Minute Takeaway on Newer Antiseizure Medications
Key clinical points:
- Newer antiseizure medications match older agents in seizure control for most focal epilepsy syndromes but do not consistently outperform them on raw efficacy endpoints.
- Tolerability favors second- and third-generation agents, with fewer pharmacokinetic interactions and reduced long-term metabolic and cognitive burden.
- Valproate retains an efficacy advantage in idiopathic generalized epilepsy but carries the highest teratogenic and neurodevelopmental risk reported in any modern pregnancy registry.
- Lamotrigine and levetiracetam show the most reassuring pregnancy data and have become preferred first-line agents for women of reproductive age.
- Drug choice should integrate seizure syndrome, comorbidity profile, drug-interaction landscape, and reproductive plans rather than treating older and newer agents as interchangeable.
Why Newer Antiseizure Medications Matter
Epilepsy affects roughly 50 million people worldwide. Antiseizure medication choice remains the dominant determinant of long-term seizure control and quality of life. The arrival of newer antiseizure medications over the past three decades created expectations of better efficacy, fewer side effects, and safer use in pregnancy.
Whether those expectations have been met varies by drug, by seizure type, and by patient population. Older first-generation agents — phenytoin, carbamazepine, valproate, and phenobarbital — remain widely prescribed, particularly where cost considerations favor first-generation drugs. They retain well-documented efficacy across decades of clinical use.
Newer agents now account for the majority of new prescriptions in North America and Europe. The shift has been driven less by clear efficacy superiority and more by tolerability advantages and pregnancy safety considerations that have emerged over twenty years of post-marketing data.
For clinicians the practical question has shifted. The relevant question is no longer whether newer antiseizure medications work, but how they compare with older agents on the three dimensions that actually drive prescribing decisions: head-to-head efficacy, side-effect burden, and reproductive safety.
Evidence Reviewed
This synthesis draws on landmark pragmatic randomized trials, large prospective pregnancy registries, and pivotal regulatory studies. Selection prioritized head-to-head comparisons of newer antiseizure medications against older agents in new-onset epilepsy populations and reproductive cohorts with multi-year follow-up.
Older first-generation agents are represented by carbamazepine, phenytoin, valproate, and phenobarbital. Newer agents include lamotrigine, levetiracetam, lacosamide, oxcarbazepine, topiramate, zonisamide, and the third-generation drugs brivaracetam, perampanel, eslicarbazepine, and cenobamate.
| Study / Cohort | Design | n | Population | Comparators | Primary Outcome |
|---|---|---|---|---|---|
| SANAD I — focal arm | Pragmatic RCT | 1,721 | New-onset focal | LTG vs CBZ vs OXC vs TPM vs GBP | LTG non-inferior to CBZ; better tolerated |
| SANAD I — generalized arm | Pragmatic RCT | 716 | New-onset generalized / unclassified | VPA vs LTG vs TPM | VPA superior on time-to-treatment failure |
| SANAD II — focal arm | Pragmatic RCT | 990 | New-onset focal | LTG vs LEV vs ZNS | LTG superior on time-to-12-month remission |
| SANAD II — generalized arm | Pragmatic RCT | 520 | Generalized / unclassified | LEV vs VPA | VPA superior on time-to-treatment failure |
| KOMET | RCT | 1,688 | New-onset adult epilepsy | LEV vs CBZ-CR / VPA-CR | LEV not superior on time-to-treatment failure |
| EURAP registry | Prospective cohort | >7,000 | Pregnant women on monotherapy | Eight major ASMs | Dose-dependent MCM rates; VPA highest |
| NEAD study | Prospective cohort | 309 | Children with in utero ASM exposure | VPA vs CBZ vs LTG vs PHT | VPA lowest IQ at age 6 |
| North American AED Pregnancy Registry | Prospective cohort | >10,000 | Pregnant women on monotherapy | All major ASMs | Confirms VPA highest MCM risk |
| UK and Ireland Epilepsy and Pregnancy Registers | Prospective cohort | >9,000 | Pregnant women on ASM | All major ASMs | LTG and LEV reassuring; VPA highest risk |
| Brivaracetam pivotal trials (pooled) | 3 RCTs | ~1,560 | Refractory focal epilepsy | BRV vs placebo (adjunctive) | Modest seizure-reduction over placebo |
CBZ = carbamazepine; CBZ-CR = carbamazepine controlled-release; LTG = lamotrigine; LEV = levetiracetam; OXC = oxcarbazepine; TPM = topiramate; GBP = gabapentin; ZNS = zonisamide; VPA = valproate; VPA-CR = valproate controlled-release; PHT = phenytoin; BRV = brivaracetam; MCM = major congenital malformation; ASM = antiseizure medication.
Key Findings on Newer Antiseizure Medications
Insight 1 — Efficacy Parity Across Most Seizure Types
Across pragmatic randomized trials, newer antiseizure medications have generally achieved efficacy comparable to older first-generation agents in focal epilepsy. SANAD I found lamotrigine non-inferior to carbamazepine on time-to-treatment failure. Lamotrigine remained the best performer in SANAD II’s focal arm fourteen years later, outperforming levetiracetam on time-to-12-month remission.
The KOMET trial randomized 1,688 adults with new-onset epilepsy to levetiracetam, controlled-release carbamazepine, or controlled-release valproate. Levetiracetam did not show superiority on time-to-treatment failure. The pattern across trials is consistent: newer antiseizure medications have not displaced older agents on raw seizure-control endpoints in focal epilepsy.
Generalized epilepsy is the notable exception. Valproate outperformed both lamotrigine and topiramate in SANAD I’s generalized arm and outperformed levetiracetam in SANAD II’s generalized arm. Across both trials, valproate retained an efficacy advantage of clinical magnitude in idiopathic generalized epilepsy.
Synthesis: Across new-onset focal epilepsy, newer antiseizure medications produce seizure outcomes broadly equivalent to older agents. Valproate remains modestly more effective than newer agents in idiopathic generalized epilepsy.
Insight 2 — Tolerability Profiles Favor Newer Agents, With Important Exceptions
Where newer antiseizure medications consistently outperform older agents is tolerability. SANAD I’s headline finding was that lamotrigine produced fewer treatment withdrawals than carbamazepine despite similar seizure control. SANAD II reinforced the pattern: lamotrigine had the lowest discontinuation rate among the three focal-arm comparators.
Older drugs carry well-documented long-term burdens. Phenytoin causes gingival hyperplasia, hirsutism, osteopenia, and cerebellar toxicity at supratherapeutic levels. Carbamazepine and phenytoin are potent hepatic enzyme inducers, complicating co-medication for hormonal contraception, anticoagulation, and chronic comorbid disease.
The tolerability advantages of newer antiseizure medications come with agent-specific caveats. Lamotrigine carries an idiosyncratic Stevens-Johnson and toxic epidermal necrolysis risk that requires slow titration. Levetiracetam is associated with irritability, depression, and behavioral disturbance in roughly 10 to 15 percent of users. Perampanel carries a boxed warning for psychiatric and behavioral adverse effects.
Synthesis: Newer antiseizure medications offer better overall tolerability driven by reduced enzyme induction, fewer drug interactions, and lower long-term metabolic effects. Agent-specific safety signals — rash with lamotrigine, behavioral effects with levetiracetam and perampanel — require individualized counseling.
Insight 3 — Pregnancy Data Have Reshaped Reproductive Counseling
Pregnancy registry data represent the strongest evidence base supporting newer antiseizure medications in reproductive-age women. EURAP, the North American AED Pregnancy Registry, and the UK and Ireland Epilepsy and Pregnancy Registers have collectively followed more than 25,000 pregnancies. They converge on a consistent ordering of major congenital malformation risk across antiseizure agents.
Valproate carries the highest malformation rate, reaching roughly 10 percent at daily doses above 1,500 mg in EURAP. The NEAD cohort documented dose-dependent neurodevelopmental impairment after in utero valproate exposure, with mean IQ at age 6 reduced relative to other antiseizure agents. Phenobarbital and topiramate are also associated with elevated malformation rates in registry data.
Lamotrigine and levetiracetam consistently show major congenital malformation rates comparable to background population risk, approximately 2 to 3 percent across registries. NEAD confirmed that children exposed in utero to lamotrigine had higher mean IQ at age 6 than those exposed to valproate. These findings have driven regulatory restrictions on valproate use in women of childbearing potential across the United Kingdom, European Union, and Canada.
Key Distinction
Pregnancy data for the newest third-generation agents — brivaracetam, perampanel, eslicarbazepine, and cenobamate — are still maturing. Where reassuring large-cohort data already exist, they support lamotrigine and levetiracetam as the most evidence-supported choices in pregnancy.
The persistence of valproate’s efficacy advantage in idiopathic generalized epilepsy likely reflects its broad mechanism of action. Valproate enhances GABA neurotransmission, blocks voltage-gated sodium channels, and modulates T-type calcium channels — a multi-target profile well-suited to the diverse seizure types within generalized syndromes (absence, myoclonic, and generalized tonic-clonic).
Levetiracetam and lamotrigine, while effective in many patients with generalized seizures, have shown lower aggregate efficacy on time-to-treatment-failure endpoints, which is the comparator that has favored valproate across SANAD I and SANAD II. Whether this gap reflects true biological superiority or trial-design factors remains debated. The consistency of the finding across two large pragmatic trials does support a real effect.
Carbamazepine, phenytoin, and phenobarbital are potent inducers of CYP3A4, CYP2C9, and UGT enzymes. This accelerates the clearance of co-administered drugs including direct oral anticoagulants, several oral contraceptives, immunosuppressants, statins, and many cardiac and antineoplastic agents.
The clinical consequences range from contraceptive failure to subtherapeutic anticoagulation. In contrast, levetiracetam and brivaracetam have minimal CYP-mediated interactions, and lacosamide has a modest interaction profile. This consideration is a major driver of the shift toward newer antiseizure medications in patients with polypharmacy or anticoagulation needs.
EURAP data show that valproate teratogenicity rises sharply with daily dose. Major congenital malformation rates are roughly 5 to 6 percent at doses below 700 mg per day and rise to approximately 10 percent at doses above 1,500 mg per day. The dose-response gradient is steeper than for any other antiseizure agent studied.
The NEAD study further demonstrated that neurodevelopmental outcomes follow a similar dose-dependent pattern, with measurable IQ reduction at age 6 in children exposed to higher maternal doses. Current regulatory guidance in the United Kingdom, European Union, and Canada requires documented counseling and a pregnancy-prevention program for any woman of childbearing potential prescribed valproate.
Evidence Quality and Consistency
The evidence supporting comparative claims about newer antiseizure medications varies substantially by domain. Pregnancy data are the strongest, with multiple large prospective registries producing concordant findings. Comparative tolerability data are also well-supported. Direct comparisons between two newer agents are the weakest domain.
What the Evidence Does Not Show
Several important questions about newer antiseizure medications remain inadequately answered by current evidence. These gaps shape areas where clinical judgment must operate without firm comparative data.
Open Questions
- Long-term outcomes beyond ten years are sparse for nearly all third-generation antiseizure agents.
- Direct comparative trials between newer agents — lacosamide versus levetiracetam, brivaracetam versus lacosamide, cenobamate versus established agents — are largely absent.
- Pregnancy registry data for brivaracetam, perampanel, eslicarbazepine, and cenobamate are still accumulating and currently insufficient to draw firm conclusions.
- Neurodevelopmental outcomes in children exposed in utero to the newest agents have not been systematically studied at school age.
- Cost-effectiveness comparisons vary substantially by setting, and generic availability has altered the economic calculus over time.
- Whether the efficacy difference in idiopathic generalized epilepsy reflects a true biological signal or trial-design artifact remains debated.
The absence of high-quality head-to-head data between newer antiseizure medications is the most consequential gap for practicing clinicians. Most prescribing decisions in current practice rely on indirect comparisons, expert consensus, and patient-specific factors rather than direct randomized evidence.
Practical Implications
Based on the current evidence, several practical patterns emerge for selecting newer antiseizure medications in clinical practice. These reflect what the data support rather than directive recommendations.
Evidence Supports Lamotrigine or Levetiracetam First-Line in Reproductive-Age Women
Across three large prospective pregnancy registries, lamotrigine and levetiracetam show major congenital malformation rates comparable to background population risk. Both have substantial reproductive-safety data accumulated over more than two decades of clinical use.
Lamotrigine Remains the Most Evidence-Supported First-Line for Adult Focal Epilepsy
SANAD I and SANAD II have repeatedly identified lamotrigine as offering the best balance of efficacy and tolerability across new-onset focal epilepsy. Slow titration to mitigate idiosyncratic rash risk is a recognized trade-off in pragmatic practice.
Valproate Retains a Defined Role in Idiopathic Generalized Epilepsy Outside Reproductive Years
SANAD I and SANAD II both demonstrate valproate’s superior efficacy in idiopathic generalized epilepsy. Use should be reserved for men and post-menopausal women, with documented counseling and pregnancy-risk-minimization in any woman of childbearing potential.
Newer Antiseizure Medications Show Advantages When Drug Interactions Drive Selection
Levetiracetam, brivaracetam, and lacosamide have minimal CYP-mediated interactions. They are preferred over enzyme-inducing older agents when polypharmacy, anticoagulation, hormonal contraception, or transplant immunosuppression is part of the clinical picture.
Evidence Grade and Bottom Line
Overall Evidence Grade: Moderate to Strong
Strong evidence supports the comparative pregnancy-safety ordering across antiseizure agents and the tolerability advantage of lamotrigine over carbamazepine in focal epilepsy. Moderate evidence supports valproate’s efficacy advantage in idiopathic generalized epilepsy. Comparative data between newer antiseizure medications themselves are limited.
Bottom Line
- For new-onset focal epilepsy, lamotrigine offers a reasonable balance of efficacy and tolerability and remains the most evidence-supported first-line choice across two large pragmatic randomized trials.
- Levetiracetam offers similar efficacy to older comparators in focal epilepsy, with the advantage of rapid titration and minimal pharmacokinetic interactions, but a notable behavioral adverse-effect profile.
- Valproate remains more effective than newer agents in idiopathic generalized epilepsy but should generally be avoided in women of childbearing potential because of teratogenic and neurodevelopmental risk.
- Pregnancy data consistently favor lamotrigine and levetiracetam, with major congenital malformation rates comparable to baseline population risk across multiple large prospective registries.
- Direct comparative data between newer agents are limited, and selection often hinges on tolerability profile, comorbidity, and patient priorities rather than randomized evidence.
Article Information and References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000-1015. DOI: 10.1016/S0140-6736(07)60460-7
- Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016-1026. DOI: 10.1016/S0140-6736(07)60461-9
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363-1374. DOI: 10.1016/S0140-6736(21)00247-6
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375-1386. DOI: 10.1016/S0140-6736(21)00246-4
- Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. 2013;84(10):1138-1147. DOI: 10.1136/jnnp-2011-300376
- Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538. DOI: 10.1016/S1474-4422(18)30107-8
- Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244-252. DOI: 10.1016/S1474-4422(12)70323-X
- Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692-1699. DOI: 10.1212/WNL.0b013e3182574f39
- Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029-1034. DOI: 10.1136/jnnp-2013-306318
- Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology. 2015;85(10):866-872. DOI: 10.1212/WNL.0000000000001772
- Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890-1898. DOI: 10.1111/epi.13212
- Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy. Report of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):82-90. DOI: 10.1212/WNL.0000000000005756